Navigation Links
Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer
Date:6/10/2013

BURLINGTON, Mass., June 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the effect of an emerging therapy on key efficacy endpoints, including time to disease progression and overall survival, has the most influence over surveyed U.S. and European oncologists' prescribing decisions for platinum-resistant advanced ovarian cancer. The emerging agents for this indication—Roche/Genentech/Chugai's Avastin (which is already approved in Europe for recurrent platinum-sensitive ovarian cancer), Amgen/Takeda Pharmaceutical's trebananib, Merck/Endocyte's vintafolide and AstraZeneca's olaparib—are all expected to offer efficacy advantages over currently available therapies used to treat platinum-resistant advanced ovarian cancer.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Decision Base 2013 report entitled Ovarian Cancer (Platinum-Resistant Advanced): Are Emerging Targeted Therapies Poised to Fill the Significant Unmet Need for This Difficult-to-Treat Patient Population?, finds that surveyed U.S. oncologists would prescribe Avastin in combination with either weekly paclitaxel (Bristol-Myers Squibb's Taxol, generics) or Janssen Biotech's Doxil/Caelyx to a total of 55 percent of their drug-treated patients with platinum-resistant advanced ovarian cancer.

The report also finds that surveyed managed care organization (MCO) pharmacy directors are receptive to novel therapies that offer an improvement in progression-free survival (PFS) in this patient population. Based on clinical data and thought-leader opinion, Avastin in combination with chemotherapy is in position to offer the PFS benefit that the majority of surveyed U.S. payers indicated would be necessary for widespread inclusion on MCO formularies.

"The platinum-resistant advanced ovarian cancer population represents a patient population with high unmet need," said Decision Resources Senior Analyst Gemma McConnell, Ph.D. "Current treatment consists of a non-platinum chemotherapy monotherapy, which typically result in low tumor response rates and a short progression-free interval. Taking together positive Phase III clinical data and interviewed experts' opinion, Avastin in combination with chemotherapy is poised to address this unmet need."

About Decision Resources
Decision Resources ( www.decisionresources.com ) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Emerging Pharma at ChemOutsourcing 2013 in Record Numbers for Upcoming September Show
2. Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer
3. Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes
4. NextDocs Launches QuickStart for Emerging Growth Companies
5. Treatment Adherence Emerging as Critical Theme in Improving Quality and Cost of US Healthcare
6. For Treatment of Extensive-Disease Small-Cell Lung Cancer (ED-SCLC), No Emerging Therapy is Likely to Replace Etoposide/Carboplatin as the Standard of Care Before 2022
7. Details of New Synthetic Vaccine for Emerging H7N9 Threat Revealed at BIO International Convention in Chicago, April 22-25
8. GlaxoSmithKline and A*STARs Institute of Chemical Engineering and Sciences to Develop new Medicines for Emerging Markets
9. For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
10. Emerging Precision Medicine Powerhouse Changes Name to Increase Visibility and Overall Awesomeness
11. Emerging Data From Upsher-Smiths CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/5/2017)... Kohll,s Pharmacy & Homecare is the first distributor of ... . The Raizer is a simple battery operated mobile ... an almost-standing position within a few minutes. The ... and does not require any extra effort besides a ... can operate it, and lightweight and portable so ...
(Date:6/1/2017)... BELL, Pa. , June 1, 2017 ... (PRN) and Veterinarian Recommended Solutions (VRS), and KD Pharma ... investment in Nutriceutical Holdings by KD Pharma Group. KD ... Holdings with the option to acquire the entire company. ... partner in KD. They are committed to growing the ...
(Date:5/30/2017)... TEL AVIV, Israel , May 30, 2017 /PRNewswire/ ... clinical stage pharmaceutical Company specializing in the development ... management will present a company overview at three ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... Anyone with a remote control has seen ... can do it, you the flipper will get rich in no time. But what ... wrong things can get for the buyer of a flipped house. An email recently ...
(Date:6/28/2017)... Philadelphia, PA (PRWEB) , ... June 28, 2017 ... ... will host a one-day corporate governance program for mid-market executives as a kick-off ... will be held Sunday, Sept. 24, 2017 on the University of Pennsylvania campus, ...
(Date:6/28/2017)... ... 28, 2017 , ... Canadian Zeolite Corp. (the “Company”) (TSX.V: ... study conducted by the University of Saskatchewan in partnership with PotashCorp, Agrium and ... groundwater. As a part of the study, batch adsorption experiments were conducted with ...
(Date:6/28/2017)... ... June 28, 2017 , ... Designers ... to communities in northern Virginia and DC, is announcing a cooperative charity event ... with Alzheimer’s and other disorders that lead to memory impairment. , The Insight ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... ... a cosmetic treatment, according to survey data released today by the American ... Cosmetic Dermatologic Procedures indicates the percentage of consumers considering a cosmetic medical ...
Breaking Medicine News(10 mins):